Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Genetics Clear all

Conditions: Hematologic Malignancy, Solid Tumor, Sickle Cell Disease, Aplastic Anemia, Immune Deficiency, Metabolic Disorder
Interventions: Let's Get REAL; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 83
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Tuberous Sclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions: BGJ398 (infigratinib); Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Colorectal Cancer
Interventions: microsatellite instability analysis; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 49 Years
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 71
States / cities: Mobile, Alabama • Colton, California • Duarte, California + 52 more

Conditions: Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
Interventions: Vorinostat (SAHA), Velcade (PS-341, Bortezomib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis Type 1
Interventions: CogmedRM, Mobymax; Other
Lead sponsor: Kristina Hardy; Other
Eligibility: 8 Years to 16 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Li-Fraumeni Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 29 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Basal Cell Nevus Syndrome, Gorlin Syndrome
Interventions: GDC-0449; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 35 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Oakland, California • New York, New York

Conditions: Lung Neoplasms, Carcinoma Non-small-cell Lung, Adenocarcinoma
Interventions: Multifocal Lung Adenocarcinoma; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Leukemia
Interventions: PEG-IFNá-2a; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Genes, Sporadic Chordoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 6 Years to 99 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tuberous Sclerosis, Angiolipoma
Interventions: everolimus (RAD001); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glioma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: Exicorilant, Enzalutamide, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more

Conditions: Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions: Galinpepimut-S, Nivolumab, Sargramostim; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Brain Neoplasm, Primary, Brain Neoplasms, Malignant, Brain Neoplasms, Benign
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC); Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Regorafenib, Venetoclax; Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: Invitae multi-cancer gene panel; Diagnostic Test
Lead sponsor: Invitae Corporation; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Lakewood, Colorado + 13 more

Conditions: Neurofibromatosis 1
Interventions: Lovastatin, placebo pill; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 10 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Interventions: Nucleus Profile ABI541 Auditory Brainstem Implant; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 12 Years to 80 Years
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 30 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more

Search by objective public record fields.

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer

Study of Skin Tumors in Tuberous Sclerosis

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Genetic Study of Young Patients With Colorectal Cancer

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1

Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

Treatment of Multifocal Lung Adenocarcinoma

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Risk Factors for Adult-Onset Brain Tumors

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

iCAT for Recurrent/Refractory/HR Solid Tumors